 Sierra Oncology Inc NASDAQ: SRRA has acquired an exclusive global license from AstraZeneca Plc NASDAQ: AZN for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022. 